Literature DB >> 426200

Intraoperative autotransfusion in major vascular surgery.

D C Brewster, J J Ambrosino, R C Darling, J K Davison, D F Warnock, A R May, W M Abbott.   

Abstract

The use of intraoperative autotransfusion provides a safe and cost-effective means of salvaging operative blood loss and reducing or eliminating the use of stored homologous bank blood with its inherent difficulties and risks. The risk of disease transmission or various reactions is minimized. Autotransfusion provides a readily available, more physiologic, and at times life-saving source of blood for patients with rare blood types or patients in whom time does not permit adequate cross-matching. This technique is acceptable to most sects of Jehovah's Witnesses, who normally refuse homologous blood. Our experience during the past six years with autotransfusion in major vascular surgery reveals a mean slavage equivalent to five units of blood loss, and avoidance of using any bank blood in almost half of elective patients. No significant problems occurred due to hemolysis, coagulation abnormalities, or particulate/air emboli, nor any morbidity or mortality specifically related to autotransfusion. We conclude that wider and more frequent use of autotransfusion technics is appropriate.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 426200     DOI: 10.1016/0002-9610(79)90122-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Intraoperative reinfusion of whole blood using a new autoinfusion device.

Authors:  B Garry; S Lisman; W H Wurm
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

Review 2.  Anaesthesia for abdominal aortic surgery--a review (Part II).

Authors:  A J Cunningham
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

3.  Intraoperative autotransfusion. Experience in 725 consecutive cases.

Authors:  M M Keeling; L A Gray; M A Brink; V K Hillerich; K I Bland
Journal:  Ann Surg       Date:  1983-05       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.